Rhodamine B as a mitochondrial probe for measurement and monitoring of mitochondrial membrane potential in drug-sensitive and -resistant cells

Journal of Biochemical and Biophysical Methods

Volumn 57, Issue 1, 2003, Pages 1-16

  Reungpatthanaphong, Paiboon ^a   Dechsupa, Samarn ^a   Meesungnoen, Jintana ^a   Loetchutinat, Chatchanok ^a   Mankhetkorn, Samlee ^a  

^a BURAPHA UNIVERSITY   (Thailand)

Author keywords

3 (4,5 Dimethyl 2 thiazolyl) 2,5 diphenyl 2H tetrazolium bromide (MTT); Cyclosporin A (CsA); Mitochondrial membrane potential ( m); Multidrug resistance associated protein (MRP1); P glycoprotein (P gp); Rhodamine B; Spectrofluorometry

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOSINE TRIPHOSPHATE; PIRARUBICIN; RHODAMINE B;

ARTICLE; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG SENSITIVITY; FLUORESCENCE; HUMAN; HUMAN CELL; KINETICS; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOLECULAR PROBE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SPECTROFLUOROMETRY;

EID: 0038771201     PISSN: 0165022X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-022X(03)00032-0     Document Type: Article

References (31)

1. Bradley G., Juranka P.F., Ling V. Mechanism of multidrug resistance. Biochim. Biophys. Acta. 948:1988;87-128.
2. Ambudkar S.V., Dey S., Hrycyna C.A., Ramchandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and aspects of the multidrug transporter. Annu. Rev. Phamacol. Toxicol. 39:1999;361-398.
3. Almquist K.C., Loe D.W., Hipfner D.R., Mackie J.E., Cole S.P.C., Deeley R.G. Characterization of the Mr 190,000 multidrug resistant protein (MRP) in drug-selected and transfected human tumor cells. Cancer Res. 55:1995;102-110.
4. Miccadei S., Fanciulli M., Bruno T., Paggi M.G., Floridi A. Energy metabolism of adriamycin-sensitive and -resistant Ehrlich ascites tumor cells. Oncol. Res. 8:1996;27-35.
5. Dorward A., Sweet S., Moorehead R., Singh G. Mitochondrial contributions to cancer cell physiology: redox balance, cell cycle, and drug resistance. Bioenerg. Biomembr. 29:1997;385-392.
6. Mieminen A.L., Saylor A.K., Herman B., Lemasters J.J. ATP depletion rather than mitochondrial mediates hepatocyte killing after metabolic inhibition. Am. J. Physiol. 267:1994;67-74.
7. Jia L.B., Kelsey S.M., Grahn M.F., Jiang X., Newland A.C. Increased activity and sensitivity of mitochondrial respiratory enzymes to tumor necrosis factor α-mediated inhibition is associated with increased cytotoxicity in drug-resistant leukemic cell lines. Blood. 87:1996;2401-2410.
8. Broxterman H.J., Pinedo H.M. Energy metabolism in multidrug resistant tumor cells: a review. J. Cell. Phamacol. 2:1991;239-247.
9. Mankhetkorn S., Dubru F., Hesschenbrouck J., Fiallo M., Garnier-Suillerot A. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mol. Pharmacol. 49:1996;532-539.
10. Zinkewich-Peotti K., Andrews P.A. Loss of cis-diaminedichloroplatinum (II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance. Cancer Res. 52:1992;1902-1906.
11. Rottenberg H., Wu S. Quantitative assay by flow cytometry of the mitochondrial membrane potential in intact cells. Biochim. Biophys. Acta. 1404:1998;393-404.
12. Shtil A.A., Grinchuk T.M., Tee L., Mechetner E.B., Ignatova T.N. Overexpression of P-glycoprotein is associated with a decreased mitochondrial transmembrane potential in doxorubicin-selected K562 human leukemia cells. Int. J. Oncol. 17:2000;387-397.
13. Vergote J., Moretti J.L., De Vries E.G.E., Garnier-Suillerot A. Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. Eur. J. Biochem. 252:1998;140-146.
14. Eytan G.D., Regev R., Oren G., Hurwitz C.D., Assaraf Y.G. Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate. Eur. J. Biochem. 248:1997;104-112.
15. Hagen T.M., Yowe D.L., Bartholomew J.C., Wehr C.M., Do K.L., Park J.Y.et al. Mitochondrial decay in hepatocytes from old rats: membrane potential declines, heterogeneity and oxidants increase. Proc. Natl. Acad. Sci. U. S. A. 94:1997;3064-3069.
16. Loew L.M., Tuft R.A., Carrington W., Fay F.S. Imaging in five dimension: time-dependent membrane potentials in individual mitochondria. Biophys. J. 65:1993;2269-2270.
17. Russell C., Scaduto J.R., Lee W.G. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys. J. 76:1999;469-477.
18. Zilstra J.G., De Vries E.G.E., Mulder N.H. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 47:1987;1780-1784.
19. Lozio C.B., Lozio B.B. Human chronic myelogenous leukemia cell line positive Philadelphia chromosome. Blood. 45:1975;321-334.
20. Tsuro T., Iida H., Kawataba H., Oh-Hara T., Hamada H., Utakoji T. Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isoclones. Jpn. J. Cancer Res. 77:1986;682-687.
21. Muller M., Meijer C., Zaman G.J.R., Borst P., Scheper R.J., Mulder N.H.et al. Overexpression of the gene encoding the multidrug-resistance-associated protein results in increased ATP-dependence glutathione S-conjugate transport. Proc. Natl. Acad. Sci. U. S. A. 91:1994;13033-13037.
22. Versantvoort C.H.M., Withoff S., Broxterman H.J., Kuiper C.M., Scheper R.J., Mulder N.H.et al. Resistance associated factors in human small cell lung carcinoma GLC4 sublines with increasing adriamycin resistance. Int. J. Cancer. 61:1995;375-380.
23. Kimmich G., Randles J., Brand J. Assay of picomole amounts of ATP, ADP, and AMP using the luciferase enzyme system. Anal. Biochem. 69:1975;187-192.
24. Berridge M.V., Tan A.S. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphynyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch. Biochem. Biophys. 303:1993;474-482.
25. Max H., Gunther K.V., Haim T., Ken T., Ted L. Membrane potential differences between adriamycin-sensitive and -resistance cells as measured by flow cytometry. Biochem. Pharmacol. 38:1989;305-312.
26. Bernardi P. Modulation of the mitochondrial cyclosporin A-sensitive permeability transition pore by the proton electrochemical gradient, evidence that the pore can be opened by membrane depolarization. J. Biol. Chem. 267:1992;8834-8839.
27. Mankhetkorn S., Garnier-Suillerot A. The ability of verapamil to restore intracellular accumulation of anthraceyclines in multidrug resistant cells depends on the kinetics of their uptake. Eur. J. Pharmacol. 343:1998;313-321.
28. Marbeuf-Gueye C., Salerno M., Quidu P., Garnier-Suillerot A. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK 104P. Eur. J. Pharmacol. 391:2000;207-216.
29. Penefsky H.S. Mechanism of inhibition of mitochondrial adenosine triphosphatase by dicyclohexylcarbodiimide and oligomycin: relationship to ATP synthesis. Proc. Natl. Acad. Sci. U. S. A. 82:1985;1589-1593.
30. Sharkey S.M., Wilson B.C., Moorehead R., Singh G. Mitochondrial alterations in photodynamic therapy-resistant cells. Cancer Res. 53:1993;4994-4999.
31. Lyon R.L., Cohen J.S., Faustino P.J., Megnin F., Myers C.E. Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. Cancer Res. 48:1988;870-877.